Working Together to Understand, Protect and Restore Vision
Congratulations to Raunak Sinha, the McPherson ERI’s David and Nancy Walsh Family Professor, for his group’s latest publication in Nature Communications! In their article, Saha et al. show that light adaptation, our visual system’s ability to adjust its photoreceptors’ light sensitivity so that we can see over a range of light levels, varies across regions …
16th Annual Vision Science Symposium Friday, October 25, 2024; HSLC Room 1345 Guest Speaker: Sönke Johnsen, PhD (Biology Department, Duke University) How our cognitive and sensory biases affect our study of vision: three tales from the sea
The McPherson Eye Research Institute is excited to announce our newest funding opportunity, the Grant Accelerator Program (GAP)! Supported by the Alice McPherson Endowment Fund for the Visual Sciences, the Van Vreede McPherson ERI Greatest Needs Fund, the Robert A. Brandt Macular Degeneration Fund, and additional donors to the McPherson ERI, the Grant Accelerator Program …
Prof. Akihiro Ikeda Dept. of Medical Genetics, SMPH Timothy William Trout Professor in Eye Research Congratulations to MERI member Prof. Akihiro Ikeda (Dept. of Medical Genetics, SMPH; Timothy William Trout Professor in Eye Research) on receiving an NIH NEI grant for his project “Role of mitochondrial dynamics in rod photoreceptor cells”! Prof. Ikeda’s study will …
2nd Annual Sandra Lemke Trout Lecture and Hybrid Grand Rounds Friday, September 13th, 2024; HSLC room 1345 and Zoom Guest Speaker: Goldis Malek, PhD, FARVO, FAOPT (Duke Eye Center, Duke University) Potential Therapeutics for Age-Related Macular Degeneration: The Nuclear Option
TUESDAY, SEPTEMBER 10, 2024 – 3571 WIMR II TUESDAY, OCTOBER 8, 2024 – 1360 BIOTECH TUESDAY, NOVEMBER 12, 2024 – 3571 WIMR II Special Seminar: Three 15-minute research talks by our Kenzi Valentyn Award Recipients TUESDAY, DECEMBER 10, 2024 – 1360 BIOTECH
BlueRock Therapeutics LP, a clinical stage cell therapy company and subsidiary of Bayer AG, today announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for OpCT-001, an investigational induced pluripotent stem cell (iPSC)-based cell therapy for the treatment of primary photoreceptor diseases. Discoveries over the past …
BlueRock Therapeutics LP, a clinical stage cell therapy company and subsidiary of Bayer AG, today announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for OpCT-001, an investigational induced pluripotent stem cell (iPSC)-based cell therapy for the treatment of primary photoreceptor diseases. Discoveries over the …
Andreas Velten, PhD, Associate Professor of Biostatistics and Medical Informatics, has received a 2024 Test of Time award from SIGGRAPH, the international meeting on graphics research. The award, which was for Velten’s 2013 research paper titled Femto-Photography: Capturing and Visualizing the Propagation of Light, is given to authors of earlier SIGGRAPH meeting papers that have had …
Prof. David Gamm, Director of the McPherson Eye Research Institute, recently appeared on Wisconsin Public Radio’s Larry Meiller Show to discuss the latest research on and treatments for macular degeneration, glaucoma, optic nerve damage, and to field questions from callers on eye health. You can hear the full broadcast here.